Oppenheimer Asset Management Inc. Immuno Gen, Inc. Transaction History

Oppenheimer Asset Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$3.32 - $5.34 $30,510 - $49,074	-9,190 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$2.12 - $6.8 $1,297 - $4,161	-612 Reduced 6.24%	9,190 $31,000
Q4 2019 Feb 07, 2020	SELL	$2.25 - $5.8 $927 - $2,389	-412 Reduced 4.03%	9,802 $50,000
Q3 2019 Oct 31, 2019	SELL	$2.22 - $3.39 $1,700 - $2,596	-766 Reduced 6.98%	10,214 $25,000
Q2 2019 Aug 09, 2019	SELL	$1.8 - $3.3 $480 - $881	-267 Reduced 2.37%	10,980 $24,000
Q1 2019 Apr 24, 2019	BUY	$2.41 - $5.91 $91 - $224	38 Added 0.34%	11,247 $30,000
Q4 2018 Jan 30, 2019	SELL	$3.94 - $9.7 $3,333 - $8,206	-846 Reduced 7.02%	11,209 $54,000
Q3 2018 Oct 26, 2018	SELL	$8.6 - $11.26 $1,247 - $1,632	-145 Reduced 1.19%	12,055 $114,000
Q2 2018 Aug 10, 2018	SELL	$9.52 - $12.15 $6,778 - $8,650	-712 Reduced 5.51%	12,200 $119,000
Q1 2018 May 09, 2018	SELL	$6.7 - $12.95 $984 - $1,903	-147 Reduced 1.13%	12,912 $136,000
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $70,518 - $110,609	13,059	13,059 $100,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.